跳至主要内容
临床试验/NCT00225485
NCT00225485已完成3 期

Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression

Wyeth is now a wholly owned subsidiary of Pfizer37 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2003年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100
试验地点
37
主要终点
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy

研究概览

简要总结

Phase III study evaluating Effexor XR in elderly patients with major depression.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients diagnosed with major depression based on DSM-IV-TR
  • •Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" of HAM-D at baseline

排除标准

  • •Patients with schizophrenia or any other psychotic disorder
  • •Patients with history or presence of bipolar disorder

结局指标

主要结局

Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy

次要结局

  • Difference of total score of HAM-D17 between baseline and final-on-therapy
  • Remission rate of HAM-D17 at the final-on-therapy

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (37)

Loading locations...

相似试验